A valuation question—not a new clinical result—is behind Genmab’s latest headline.
Dated October 29, the headline asks whether Genmab may still be undervalued after its trial wins. It doesn’t provide a valuation method, new trial data, or evidence to answer that question. The supplied company-news list includes an October 28 announcement of positive interim results for a petosemtamab combination, but it doesn’t establish whether those results are the trial win referenced in the headline.
Investor takeaway: The headline raises a valuation question, but the available facts aren’t enough to determine whether Genmab is undervalued.
Genmab AS
GMAB.US
GMAB.US
Genmab AS
WealthAwesomeMarket cap
$35.09B
P/E
44.9x
52W high
$59.97
52W low
$23.62
1W change
+30.30%
Beta
0.65
Analyst Price Targets
Based on 12 analysts covering GMAB · as of Nov 2, 2026
Wall Street analysts forecast GMAB stock price to rise 13.3% over the next 12 months.
Consensus
Strong Buy4.75 / 5.00
Avg. Target
C$64.65
+13.3% Upside
Previously C$61.15 on Oct 30, 2026
Current Price
C$57.06
Last close
Analyst Breakdown (12 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on GMAB's historical volatility
30-Day Vol
83.8%
Annualized
90-Day Vol
54.7%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$68.22
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$60.56 | C$45.35 – C$80.87 |
| 60 trading days | C$64.27 | C$42.70 – C$96.75 |
| 90 trading days | C$68.22 | C$41.34 – C$112.56 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Genmab closed at US$55.57
The close was 88% of the supplied 52-week range of US$23.62 to US$59.97. Latest volume was 930,865 shares, compared with a 20-day average of 6,424,270.
Bull case
In a first interim analysis of a study in first-line recurrent or metastatic PD-L1-positive head and neck cancer, Genmab reported statistically significant, clinically meaningful improvements in overall survival and objective response with a petosemtamab combination.
Bear case
The October 29 headline provides no valuation analysis or supporting assumptions. The available facts also don’t show how the trial results could affect Genmab’s future financial performance.
The headline raises a valuation question
Genmab’s October 29 headline asks whether the company may still be undervalued after its trial wins. It poses a question, not a valuation conclusion: the headline includes no valuation model, assumptions, or new trial findings. The available facts don’t establish whether Genmab is undervalued. See the [Genmab (GMAB.US)](/stocks/gmab-us) stock page.
The supplied trial news came the day before
The company-news list includes an October 28 announcement reporting statistically significant, clinically meaningful improvements in overall survival and objective response at the first interim analysis of a petosemtamab combination study. The study involved first-line recurrent or metastatic PD-L1-positive head and neck cancer. A separate headline that day said the cancer drug cut the risk of death by 50%, but the supplied facts don’t include the comparison, study details, or context behind that figure. The October 29 valuation headline doesn’t say which trial results it refers to.
Price and volume provide context, not a valuation answer
Genmab’s last close was US$55.57, within the supplied 52-week range of US$23.62 to US$59.97 and at 88% of that range. The supplied performance figures show the stock up 30.30% over one week and 59.94% over one month. Latest volume was 930,865 shares, versus a 20-day average of 6,424,270.
The supplied fundamentals include a P/E of 44.9291 and a market capitalization of US$35,086,340,096. They don’t explain how those figures relate to the headline’s suggestion that the stock may be undervalued. Investors can review the GMAB.US stock page for the supplied company data.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
